Attacks on Pharmaceutical Improvement Patents
Washington, D.C. partner Bob Stoll and associate Nick Colic co-authored an article titled “Attacks on Pharmaceutical Improvement Patents” for Pharmaceutical Executive.
In their article, Bob and Nick provide coverage on the Term Act of 2019, and discuss how the proposed legislation would change long-term presumptions of enforceability for improvement patents in the pharmaceutical industry. They argue that what the House has proposed in its pending legislation could completely turn the long-standing presumption of patent validity on its head, at least in the context of pharmaceutical and biological products. The article seeks to raise the question: Is Congress harming pharmaceutical research by limiting enforcement of improvement patents?
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.
Meet the Authors
